Handa Pharmaceuticals Inc(TW:6620)
NT$136.50+11.00 (+8.76%)
TW:6620
Handa Pharmaceuticals Inc financials statements
NT$136.50
At close:+11.00 (+8.76%)
Handa Pharmaceuticals Inc (6620) Ratios
Handa Pharmaceuticals Inc Ratios
TW:6620's free cash flow for Q2 2026 was NT$262.00M. For the 2026 fiscal year, TW:6620's free cash flow was decreased by NT$-2.22M and operating cash flow was NT$264.22M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 36.59 | 8.72 | 12.96 | 13.07 | 10.57 |
| Quick Ratio | 36.59 | 8.55 | 12.96 | 13.07 | 10.57 |
| Cash Ratio | 15.34 | 2.48 | 3.18 | 8.07 | 8.86 |
| Solvency Ratio | 3.94 | 1.49 | 2.63 | -0.36 | -6.00 |
| Operating Cash Flow Ratio | 2.07 | 2.06 | 3.19 | -4.66 | -6.03 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 4.08B | NT$ 1.78B | NT$ 2.43B | NT$ 523.41M | NT$ 278.91M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.00 | 0.04 | 0.02 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.00 | 0.04 | 0.03 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.00 | 0.04 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.04 | 1.10 | 1.10 | 1.10 | 1.08 |
| Debt Service Coverage Ratio | 416.04 | 983.06 | 3320.64 | -87.36 | -914.99 |
| Interest Coverage Ratio | 424.24 | 849.71 | 3123.55 | -313.59 | -1094.32 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.32 | 0.29 | 0.10 | 0.24 | 0.10 |
| Net Debt to EBITDA | -1.59 | -1.14 | -0.81 | 12.15 | 1.12 |
| Profitability Margins | |||||
| Gross Profit Margin | 84.53% | 99.86% | 99.88% | 90.53% | 95.00% |
| EBIT Margin | 54.31% | 57.74% | 71.65% | -21.69% | -891.29% |
| EBITDA Margin | 63.80% | 59.00% | 72.56% | -14.01% | -771.02% |
| Operating Profit Margin | 54.02% | 50.33% | 62.68% | -44.58% | -868.42% |
| Pretax Profit Margin | 54.18% | 57.68% | 71.63% | -21.83% | -892.08% |
| Net Profit Margin | 43.36% | 56.91% | 65.70% | -20.24% | -847.17% |
| Continuous Operations Profit Margin | 43.36% | 57.13% | 65.49% | -20.24% | -847.17% |
| Net Income Per EBT | 80.02% | 98.66% | 91.72% | 92.73% | 94.97% |
| EBT Per EBIT | 100.30% | 114.62% | 114.29% | 48.97% | 102.72% |
| Return on Assets (ROA) | 12.72% | 13.74% | 23.93% | -5.06% | -49.68% |
| Return on Equity (ROE) | 13.25% | 15.17% | 26.37% | -5.55% | -53.48% |
| Return on Capital Employed (ROCE) | 16.18% | 13.06% | 24.52% | -11.82% | -54.16% |
| Return on Invested Capital (ROIC) | 12.92% | 12.86% | 22.45% | -10.82% | -50.76% |
| Return on Tangible Assets | 14.63% | 19.00% | 24.22% | -5.30% | -53.58% |
| Earnings Yield | 5.64% | 4.49% | 2.95% | -0.26% | -3.07% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.95 | 3.78 | 2.89 | 1.19 | 3.40 |
| Payables Turnover | 8.85 | 0.06 | 0.09 | 3.01 | 1.36 |
| Inventory Turnover | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 20.38 | 10.96 | 52.60 | 4.59 | 0.70 |
| Asset Turnover | 0.29 | 0.24 | 0.36 | 0.25 | 0.06 |
| Working Capital Turnover Ratio | 0.57 | 0.38 | 0.72 | 0.48 | 0.09 |
| Cash Conversion Cycle | 82.44 | 6470.97 | -3792.42 | 185.41 | -161.78 |
| Days of Sales Outstanding | 123.69 | 96.55 | 126.35 | 306.75 | 107.35 |
| Days of Inventory Outstanding | 0.00 | 12844.45 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 41.25 | 6470.03 | 3918.77 | 121.34 | 269.13 |
| Operating Cycle | 123.69 | 12941.00 | 126.35 | 306.75 | 107.35 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.58 | 3.54 | 4.98 | -1.68 | -1.50 |
| Free Cash Flow Per Share | 1.47 | 3.49 | 4.97 | -1.69 | -1.56 |
| Dividend Paid and CapEx Coverage Ratio | 0.96 | 3.34 | 708.01 | -279.12 | -25.07 |
| Capital Expenditure Coverage Ratio | 14.26 | 64.07 | 708.01 | -279.12 | -25.07 |
| Operating Cash Flow Coverage Ratio | 5.11 | 12.41 | 50.48 | -7.15 | -15.07 |
| Operating Cash Flow to Sales Ratio | 0.14 | 0.60 | 0.60 | -1.07 | -6.13 |
| Free Cash Flow Yield | 1.70% | 4.66% | 2.71% | -1.39% | -2.31% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 17.73 | 22.23 | 33.92 | -379.97 | -32.61 |
| Price-to-Sales (P/S) Ratio | 7.69 | 12.67 | 22.28 | 77.23 | 276.15 |
| Price-to-Book (P/B) Ratio | 2.35 | 3.38 | 8.94 | 21.17 | 17.43 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 58.69 | 21.48 | 36.92 | -71.90 | -43.31 |
| Price-to-Operating Cash Flow Ratio | 54.57 | 21.15 | 36.87 | -72.16 | -45.04 |
| Price-to-Earnings Growth (PEG) Ratio | 0.40 | -0.59 | -0.02 | 4.49 | 2.58 |
| Enterprise Value Multiple | 10.46 | 20.33 | 29.88 | -539.26 | -34.70 |
| Enterprise Value | 11.54B | 9.96B | 23.99B | 14.93B | 7.82B |
| EV to EBITDA | 10.46 | 20.33 | 29.88 | -539.26 | -34.70 |
| EV to Sales | 6.67 | 12.00 | 21.68 | 75.53 | 267.55 |
| EV to Free Cash Flow | 50.92 | 20.34 | 35.95 | -70.32 | -41.97 |
| EV to Operating Cash Flow | 47.35 | 20.03 | 35.89 | -70.57 | -43.64 |
| Tangible Book Value Per Share | 31.66 | 15.41 | 20.26 | 5.46 | 3.57 |
| Shareholders’ Equity Per Share | 36.62 | 22.19 | 20.52 | 5.74 | 3.87 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.20 | 0.01 | 0.08 | 0.07 | 0.05 |
| Revenue Per Share | 11.19 | 5.91 | 8.24 | 1.57 | 0.24 |
| Net Income Per Share | 4.85 | 3.37 | 5.41 | -0.32 | -2.07 |
| Tax Burden | 0.80 | 0.99 | 0.92 | 0.93 | 0.95 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.01 | 1.00 |
| Research & Development to Revenue | 0.21 | 0.35 | 0.28 | 0.91 | 7.15 |
| SG&A to Revenue | 0.10 | 0.14 | 0.09 | 0.44 | 2.49 |
| Stock-Based Compensation to Revenue | 0.01 | 0.03 | 0.01 | 0.00 | 0.01 |
| Income Quality | 0.26 | 1.04 | 0.84 | 4.90 | 0.69 |
Currency in TWD
